November 5 | 2020
Announcement from 2cureX extra general meeting
Read more
October 14 | 2020
Notice of extraordinary general meeting in 2ureX AB
Read more
October 1 | 2020
Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
August 27 | 2020
2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.
Read more
August 4 | 2020
First day for trading in TO1 series warrants
Read more
July 13 | 2020
Record date for allotment of warrants of series TO1 is set to July 17, 2020
Read more
July 6 | 2020
2cureX completes a heavily oversubscribed directed issue of approximately SEK 40 million
Read more
July 6 | 2020
2cureX AB intends to carry out a directed issue of units
Read more
July 3 | 2020
2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner
Read more
July 2 | 2020
Bulletin from the Extraordinary General Meeting in 2cureX AB (publ)
Read more
July 1 | 2020
2cureX Newsletter July’20
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 17 | 2020
Notice to attend the extraordinary general meeting of 2cureX AB (publ)
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 9 | 2020
Change of Certified Adviser to Redeye AB
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more